• A new executive order immediately suspends federal funding for "dangerous gain-of-function research" both domestically and for foreign entities in countries with insufficient biosafety measures.
  • The policy, framed as a national security imperative, specifically targets collaborations with countries like China and reverses more permissive oversight practices from the prior administration.
  • U.S. research institutions face immediate regulatory tightening, with the Office of Science and Technology Policy given 120 days to revise oversight policies for high-risk biological studies.

Efforts to restructure the U.S. approach to biological research funding have culminated in a significant policy shift, with an executive order from the Trump administration halting federal support for certain high-risk experiments. The order takes direct aim at "gain-of-function" research involving potentially pandemic pathogens, a long-controversial area of science.

The directive imposes an immediate suspension on funding for such work within the U.S. and for foreign entities operating in nations deemed to lack adequate biosafety protocols. People familiar with the matter confirmed that China is a primary focus of the foreign funding restrictions. The administration frames the move as essential to safeguarding national security and preventing economic disruptions from future pandemics, a clear reversal of the Biden administration's more flexible oversight framework.

Within 120 days, the Office of Science and Technology Policy is tasked with revising oversight policies to increase accountability and ensure regular review of high-risk research. This tightens the reins on life sciences organizations that rely on federal grants, potentially constraining innovation in some areas of biotechnology. "What we are focused on is regulatory stability and security," a senior administration official said, speaking on condition of anonymity. "This is about U.S. leadership in biosecurity."

The order has sparked a sharp debate among stakeholders. Public health and national security experts have largely welcomed the heightened oversight, citing lessons from the COVID-19 pandemic. However, some scientists within the research community caution that overly broad restrictions could hamper the development of crucial countermeasures against naturally emerging diseases. Attempts to reach representatives from several major research universities for comment were not immediately successful.

The international implications are significant, potentially slowing collaborative projects and complicating scientific diplomacy with targeted nations. The policy reflects heightened global concern about the dual-use nature of advanced biological research and aligns with a broader reassessment of biosecurity risks among Western nations. While the immediate effect is a freeze on specific funding streams, the long-term impact may be a more robust, albeit more restricted, framework for managing the risks of cutting-edge biological research.

Correction: An earlier version of this article did not specify that the OSTP has 120 days to revise oversight policies. This has been updated.